



Scabronine A, a Novel Diterpenoid Having Potent Inductive Activity of the Nerve Growth Factor Synthesis, Isolated From the Mushroom, *Sarcodon scabrosus*

Tomihisa Ohta,^{a*} Takako Kita,^b Norihiro Kobayashi,^a Yutaro Obara,^c Norimichi Nakahata,^c Yasushi Ohizumi,^c Yoshiaki Takaya,^b and Yoshiteru Oshima^b

^aDepartment of Pharmacognosy and Natural Products Chemistry, Faculty of Pharmaceutical Sciences, Kanazawa University, Takaramachi, Kanazawa 920-0934, Japan; ^bDepartment of Pharmacognosy and ^cDepartment of Pharmaceutical Molecular Biology, Faculty of Pharmaceutical Sciences, Tohoku University, Aoba, Aramaki, Aobaku, Sendai 980-8578, Japan
Email: ohta@db.s.p.kanazawa-u.ac.jp

Received 21 May 1998; revised 18 June 1998; accepted 19 June 1998

Abstract: A novel diterpenoid, scabronine A, having strong inductive activity of the nerve growth factor synthesis was isolated from the fruit body of the mushroom, *Sarcodon scabrosus* (Fr.) Karst. The stereostructure of scabronine A (**1**) was elucidated on the basis of the spectroscopic analysis of natural scabronine A and its derivatives. © 1998 Elsevier Science Ltd. All rights reserved.

Keywords: carboxylic acids and derivatives; fungi; stereochemistry; terpenes and terpenoids

Thelephoraceous brown fungus *Sarcodon scabrosus* (Fr.) Karst. which grows in coniferous and deciduous woods of Europe and Japan has been recognized as an inedible mushroom because of its strongly bitter taste which may derive from bitter terpenoids¹. During our studies on biologically active constituents of Japanese mushrooms (Basidiomycetes)², we found a new diterpenoid, scabronine A (**1**) which showed strong inductive activity of the nerve growth factor (NGF) synthesis in 1321N1 human astrocytoma cells, from *S. scabrosus*. We wish to report here the isolation and structural elucidation of **1**.

The fruit body (1.4 kg) of *S. scabrosus* was extracted with MeOH and then the extract was partitioned between *n*-hexane-EtOAc and water. The *n*-hexane-EtOAc extract was subjected repeatedly to silica gel chromatography using *n*-hexane-EtOAc or chloroform-MeOH mixed solvent system of increasing polarity. The fraction obtained with chloroform-MeOH (30:1) elution was purified twice by reversed-phase HPLC on ODS. Elution with MeOH-H₂O (7:3) gave scabronine A (**1**, 213 mg, 1.5 x 10⁻²%) as a colorless amorphous solid, mp 93.5–94.5 °C, [α]_D²³ –15.0° (c 0.92, MeOH). The molecular formula, C₂₂H₃₄O₆ was determined by HREI-MS (*m/z* 394.2357, M⁺, Δ *mmu* +0.2). Scabronine A (**1**) showed characteristic IR absorptions at 3410, 1700, 1100, 1080 cm⁻¹ implying hydroxyl and carboxyl functions. The yellow coloration with BCG reagent on TLC and the methyl ester (**2**) given with diazomethane indicated the carboxylic acid substituent in **1**.

The ¹H and ¹³C NMR spectra showed several sets of signals with the ratio of 2:1 due to equilibrium at the hemiacetal position (δ_H/δ_C 5.31/104.1 for major and 5.91/99.4 for minor isomers). The ratio was changed to 94:6³ by the methylation of **1** with diazomethane. Both

Table 1. ^1H and ^{13}C NMR spectral data for scabronine A (**1**) and the methyl ester (**2a**) in CDCl_3 .^{a)}

Scabronine A (1) ^{b)}			Methyl ester (2a)	
Position	^{13}C	^1H	^{13}C	^1H
1	33.6 (t)	1.70-1.78 (1H, m) 1.90-2.03 (1H, m)	33.8 (t)	1.68 (1H, ddd, $J=6.8, 8.1, 13.2$) 1.91 (1H, ddd, $J=7.8, 9.3, 13.2$)
2	29.7 (t)	2.43 (2H, m)	29.6 (t)	2.39 (2H, m)
3	143.7 (s)		143.1 (s)	
4	134.2 (s)		133.9 (s)	
5	37.7 (d)	2.21 (1H, $J=12.4$)	37.8 (d)	2.14 (1H, d, $J=12.3$)
6	41.9 (s)		41.6 (s)	
7	34.5 (t)	1.14 (1H, ddd, $J=2.0, 2.0, 13.6$) 1.85-2.03 (1H, m)	34.4 (t)	1.10 (1H, ddd, $J=2.6, 4.1, 14.0$) 1.96 (1H, ddd, $J=4.2, 13.6, 14.0$)
8	31.4 (t)	1.48 (1H, ddd, $J=4.8, 14.0, 14.0$) 2.15 (1H, ddd, $J=2.0, 2.0, 14.0$)	31.8 (t)	1.46 (1H, ddd, $J=4.1, 13.6, 13.6$) 2.17 (1H, ddd, $J=2.6, 4.2, 13.6$)
9	61.9 (s)		61.7 (s)	
10	32.8 (t)	1.71 (1H, ddd, $J=10.5, 12.4, 14.0$) 2.31 (1H, dd, $J=6.0, 14.0$)	32.7 (t)	1.67 (1H, ddd, $J=10.7, 12.3, 13.7$) 2.25 (1H, dd, $J=5.4, 13.7$)
11	80.1 (d)	3.29 (1H, dd, $J=6.0, 10.5$)	80.5 (d)	3.17 (1H, dd, $J=5.4, 10.7$)
12	53.4 (d)	2.60 (1H, s)	54.1 (d)	2.54 (1H, s)
13	80.7 (d)	3.89 (1H, s)	81.0 (d)	3.93 (1H, s)
14	93.4 (d)	4.02 (1H, s)	92.1 (d)	3.96 (1H, s)
15	104.1 (d)	5.29 (1H, s)	104.1 (d)	5.10 (1H, s)
16	15.1 (q)	0.85 (3H, s)	15.2 (q)	0.83 (3H, s)
17	182.7 (s)		177.4 (s)	
18	27.0 (d)	2.94 (1H, sept, $J=6.8$)	27.0 (d)	2.93 (1H, sept, $J=6.8$)
19	21.8 (q)	1.05 (3H, d, $J=6.8$)	21.8 (d)	1.03 (3H, d, $J=6.8$)
20	21.4 (q)	0.97 (3H, d, $J=6.8$)	21.4 (d)	0.96 (3H, d, $J=6.8$)
11-OMe	56.6 (q)	3.40 (3H, s)	56.5 (q)	3.39 (3H, s)
13-OMe	56.8 (q)	3.36 (3H, s)	56.7 (q)	3.36 (3H, s)
17-OMe			51.8 (q)	3.69 (3H, s)

a) ^1H and ^{13}C NMR were recorded at 500 MHz and 125 MHz, respectively.

Multiplicities in parentheses for ^{13}C signals were determined by DEPT experiments. J s were expressed in Hz.

b) Major isomer.




Figure 1

epimeric isomers could be isolated by silica gel chromatography with *n*-hexane-Et₂O (1:2) elution to give the methyl esters (**2a** and **2b**) in the ratio of 93.3:6.7. The major methyl ester (**2a**), $[\alpha]_D^{24} -29.6^\circ$ (*c* 1.1, MeOH), m/z 482.507 (M^+ , C₂₃H₃₆O₆), showed NMR signals and IR absorptions due to an acetal (δ_H/δ_C 5.10/104.1, ν 3511 cm⁻¹), three methoxys (δ_H/δ_C 3.36/56.7, 3.39/56.5 and 3.69/51.8) one of which belonged to a methoxycarbonyl (δ_C 51.8, 177.4, ν 1721 and 1198 cm⁻¹), three carbiny methines (δ_H/δ_C 3.17/80.5, 3.93/81.0 and 3.96/92.1), three methines (δ_H/δ_C 2.14/37.8, 2.54/54.1 and 2.93/27.0), five methylenes (δ_H/δ_C 1.68;1.91/33.8, 2.39;2.40/29.6, 1.10;1.96/34.4, 1.46;2.17/31.8, 1.67;2.25/32.7), three methyls (δ_H/δ_C 0.83/15.2, 0.96/21.4 and 1.03/21.8), two quaternary carbons (δ_C 41.6 and 61.7) and a fully substituted olefin (δ_C 133.9; 143.1). Six degrees of unsaturation derived from the molecular formula suggested that **2a** was a tetracyclic compound having a carbonyl and a double bond. 2D NMR analysis such as H-H and C-H COSY, COLOC and HMBC together with 1D H-H homo-decoupling experiment indicated a hemiacetal ring adjacent to a cycloheptane ring as illustrated in the gross structure **A** (Figure 1).




Figure 2

The relative stereochemistry was elucidated by the 1D differential NOE experiment as shown in Figure 2. Among those observed, the NOE between H-18 and H₂-10, H-8 and H₃-16, H-5 and H-11 suggested a chair conformation of the cyclohexane ring. This indicated that the methoxycarbonyl substituent at C-9 has an axial configuration, *S*^{*}.

The absolute stereochemistry was analyzed by the extended Mosher (¹H) method⁴. *S*- and *R*-MTPA esters of 17-*O*-methylscabronine A (**2a**) gave a reasonable distribution pattern of $\Delta\delta$ values as shown in Figure 2. Although the sign of $\Delta\delta$ value for H-14 did not follow the extended Mosher method, it went into the proper group when the O-C=O plane of the MTPA ester was twisted counterclockwise as illustrated in Figure 2. Consequently, the stereostructure **1** was established for scabronine A. Scabronine A (**1**) could be a highly oxidized analogue of allocyathin B₂ isolated from *S. scabrosus*¹.

Scabronine A (**1**) showed potent inductive activity of NGF synthesis in 1321N1 human astrocytoma cells⁵. Namely, **1** released 746 pg/mL of NGF at 100 μ M from 1321N1 cells under basal release of 147 pg/mL of NGF during two days. Furthermore, reverse transcription polymerase chain reaction (RT-PCR) revealed that **1** increased NGF mRNA by 1.99-fold in 1321N1 cells. Some NGF inducers such as catecholamines⁶, benzoquinones⁷, hericenones⁸, fellutamides⁹, kansuinin A¹⁰, pyrroloquinoline quinones¹¹ and erinacines¹² have been hitherto reported. A strong NGF inducer with low molecular size such as scabronine A (**1**) will be a useful drug for serious neuronal diseases such as Alzheimer's disease. Scabronine A (**1**) will also be helpful to clarify the mechanism of NGF synthesis and secretion.

Acknowledgment: We wish to thank Ms. Yohko Ando and members of Sendai Mushroom Society for collecting the mushrooms.

References and Notes

1. Shibata, H.; Tokunaga, T.; Karasawa, D.; Hirota, A.; Nakayama, M.; Nozaki, H.; Tada, T. *Agric. Biol. Chem.* **1989**, 53, 3373.
2. Ohta, T.; Inoue, H.; Kusano, G.; Oshima, Y. *Heterocycles*, **1998**, 47, 883, and references cited there in.
3. Determined with ¹H NMR of the methyl ester (**2**).
4. Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. *J. Am. Chem. Soc.* **1991**, 113, 4092, and references cited there in.
5. Obara *et al.*, manuscript in preparation.
6. Furukawa, Y.; Furukawa, S.; Satoyoshi, E.; Hayashi, K. *J. Biol. Chem.* **1986**, 261, 6039.
7. Takeuchi, R.; Murase, K.; Furukawa, Y.; Furukawa, S.; Hayashi, K. *FEBS Lett.* **1990**, 261, 63.
8. Kawagishi, H.; Ando, M.; Shinba, K.; Sakamoto, H.; Yoshida, S.; Ojima, F.; Ishiguro, Y.; Ukai, N.; Furukawa, S. *Phytochemistry* **1993**, 32, 175.
9. Yamaguchi, K.; Tsuji, T.; Wakuri, S.; Yazawa, K.; Kondo, K.; Shigemori, H.; Kobayashi, J. *Biosci. Biotech. Biochem.* **1993**, 57, 195.
10. Yamaguchi, K.; Uemura, D.; Tsuji, T.; Kondo, K. *Biosci. Biotech. Biochem.* **1994**, 58, 1749.
11. Yamaguchi, K.; Sasano, A.; Urakami, T.; Tsuji, T.; Kondo, K. *Biosci. Biotech. Biochem.* **1993**, 57, 1231.
12. Kawagishi, H.; Shimada, A.; Shirai, R.; Okamoto, K.; Ojima, F.; Sakamoto, H.; Ishiguro, Y.; Furukawa, S. *Tetrahedron Lett.* **1994**, 35, 1569.